

MOLECULAR DOCKING ANALYSIS OF SELECTED CELOSIA ARGENTEA CONSTITUENTS AS HUMAN TRANSFERIN MODULATOR

B.V. Febiyola Justin¹, H.Simran², Dr.N.Radhakrishnan³

¹Assistant professor, Department of Biochemistry, St.peter's institute of Higher education and Research, Avadi, Chennai- 54, Tamilnadu

²Department of Biotechnology, St.Peter's institute of Higher education and Research Avadi, Chennai- 54

³HOD, Biochemistry St.Peter's institute of Higher education and Research Avadi, Chennai- 54

Abstract:

The phytoconstituents of *Celosia argentea* has been reported to posses various biological properties. This promoted us to carry out the docking study on the 20 ligands namely CelogentineE, CelogentinH, Palmitoleic acid, Octadecanoic acid, Luteolin7Oglucoside, CelosinF, Linoleic acid, CelosinG, Hexadecanoic acid, celosinE, CelogentinK, CelogentinJ, CelogentinG, CelogentinC, CelogentinB, CelogentinF, Arachidonic acid, CelogentinD, CelogenamideA and Arachidic acid of the plant celosia argentea with the serum protein. These ligands were evaluated on the docking behavior of human transferrin protein (1A8F) using patch Dock online software. Docking and binding free energy analysis revealed that the ligand CelogentinD exhibited maximum binding energy towards human transferrin protein. The present study has paved a new insight in understanding the constituents of celosia argentea as potential iron contentor and can be used in therapeutics for iron deficiency anaemia. The leaves of the plants were dried for about a month without sunlight. A sample of single dried leaf from each plant was given to analyse the peaks of absorbance by Fourier transform Infrared Spectroscopy (FTIR) to denote the presence of metals.

Keywords: Transferrin protein, iron deficiency, ligands, Docking, Serum protein receptor, *Celosia argentea*, drug designing, CelogentinD.

1. Introduction

Iron deficiency is estimated to affect about one fifth of the world's population, and women and children are among the most severely affected. Evidence is mounting that iron deficiency anemia adversely affects brain development with measurable effects on children's behavior with learning disability, reduced work productivity, morbidity, mortality, motor development and cognition (Fikiru Dasa et al., 2018). In Chennai district of the state Tamil Nadu, south-India, 50% of school age children (5-6 years) and 37.46% of children (0-20 years) are anemic (Serena Josephine M et al., 2019). Iron bioavailability calculated using algorithms in regional diets ranged from 3.2 to 4.6 percent. *Celosia argentea* is one of unutilised plant. It is a high potential plant with 13.5 mg/100g of iron and known as a nutritious and healthy legume (Oluwafunmilayo Dorcas Adegbaaju et al, 2019). Ascorbic acid is a potent enhancer of iron absorption in humans which can counteract the inhibitory effect of phytic acid and polyphenols (Fikiru Dasa et al., 2018). Guava is a popular and easily available fruit for this community having 3111.67mg/10g of ascorbic acid (Ojukwu UP et al, 2017).

1.1. Conventional iron proportion in human body

Iron is arranged as the twenty sixth element in the periodic table and is composed of the molecular weight of about 55.85. Iron is available in abundance in the earth but in trace amount within the human body. The below table is referred for its fractions in milligram. (-Fikiru Dasa et al., 2018).

Table.1.1. Iron Proportion

Discrete factor	Iron Portion (mg)
Infants	250
Adult female	2000-3000
Adult male	3000-4000

1.2. Distribution of iron content in different establishments in the body

(-Fikiru Dasa et al., 2018).

Table.1.2. Iron establishment.

S.No.	Disposition	Percentage conformation
1.	Haemoglobin	60
2.	Myoglobin	5
3.	Heme and non-heme enzymes	5
4.	Ferritin	20
5.	Hemisederin	10

The iron has a major key function in the energy metabolism and in physiochemical processes. In the biological mechanisms such as the citric acid cycle, it exists in the enzyme aconitase, NADH dehydrogenase and succinate dehydrogenase by forming a linkage with sulphur in the mitochondria and cytosol of the cell for the energy production (sugar-breakdown) by ATP synthesis. Hence it is the bit-part of all the cells in the human body. Iron is entangled in the oxidation and reduction reaction by accepting and donating electrons. The physiochemical role of iron denotes its distribution of oxygen to the various hunks of the body through haemoglobin. Fe prevents Hydrogen peroxide accumulation alongside breaking the bond between hydrogen and oxygen.

1.3. Mechanism of Iron absorption

(-Richard et al.,1998) When a cuisine containing iron content is consumed, the iron is digested and absorbed by the duodenum and proximal jejunum within the small intestine. The heme and non-heme iron is engrossed by the process of endocytosis. Ferritin is preoccupied by transferrin receptor.

Iron deficiency anaemia predominantly occurs due to the reduced intake of iron, slight absorption and blood loss (because blood contains red-blood cells with iron containing haemoglobin).

In the early stage of anaemia, the serum iron concentration in transferrin protein is standard at a normal condition. If left unnoticed, it gradually decreases followed by moderate decrease in the heme iron as the next pace leading to the severe stage of anaemia. The symptoms include impaired physical activity, reduced mood, reduced cognitive function, poor pregnancy related outcomes, weakness, fatigue, dyspnea, palpitations, sensitivity to cold, abnormalities in oral cavity and gastrointestinal tract and reduced capacity in work. The adolescent women are more susceptible to the disease. The infants, children, teenagers, women of child bearing (menstruation and child bearing in fertile women) are the most commonly affected.

Excessive consumption of iron content results in iron overload in which iron floats without binding to serum protein. It causes bacterial infection and cardiomyopathy. Its consequences in inadequate synthesis of iron-binding protein. On the other hand if the iron absorption is regulated in a controlled manner, its excretion is unconstrained. This problem can be limited by appropriate diet and biological system.

1.4. Elucidation of the substances inhibiting iron absorption

(-Fikuru Dasa et al.,2018)

Table.1.3. Iron absorption inhibiting components

S.No.	Inhibiting module
1.	Presence of anti-nutrients such as phytates and tannin) in cereal based food products.
2.	Iron-binding phenolic compounds in tea, coffee, red wine.
3.	Some leafy vegetables, herbs, nuts and legumes.
4.	Calcium
5.	Soy protein

It is reported that 165mg of calcium inhibits fifty to sixty percentage of heme and non-heme iron absorption. The maximum diffidence occurs at the time when 300mg of calcium is specified in consumption. The intensity of inhibition remains stable at the latter level (300milligram). The duration for the exposure of inhibition pertains about two hours. 1000mg of Ca in twelve weeks showed no harmful effects.

Iron absorption is equal to nought when the iron containing edible product such as bran-bread comprises of high-phytate content. 20mg of polyphenols present in black tea produces sixty six percentage of diffidence. Leaves of lead tree in Thailand known as Yog kratin make ninety percent inhibition. The plant species spinach and aubergin are gregarious inhibitors of iron absorption. Thirty six percentage of inhibition in iron absorption takes place when tea is consumed along with milk. Meanwhile twenty percentage of iron absorption is restricted when tea is exclusively utilized. Coffee inhibits ten percent of iron absorption due to the presence of chlorogenic acid. (-Richard et al.,1998).

1.5. Elucidations of the enhancers of iron absorption

(-Fikuru Dasa et al.,2018)

Table.1.4. Iron absorption supplements

S.No.	Enhancement module
1.	Ascorbic acid
2.	Meat, fish and seafood

3.	Organic acids such as tartaric acid, citric acid, malic acid, lactic acid.
----	--

Ascorbic acid is potent enough as to enhance non-heme-iron absorption of about twenty five percent when consumed in the ratio of 2:1 along with the standard meal. Meat is the only exceptional supplement for heme iron absorption because of gastric acidic effects and chelation. Alcohol is another molecule for the increment of serum transferrin iron, ferritin, hence the chronic alcohol abusers have calculatedly higher ferritin concentrations compared to the non-drinkers.

Table.1.5.Provenance of iron in fruits and vegetables

(-Bhuvaneshwari.S et al.,2015)

S.no.	Source	Mean Iron content (mg/100g)
1.	Apple	0.92
2.	Fig	1.32
3.	Ground nut	1.27
4.	Soya bean	1.65
5.	Dates	0.52
6.	Fenugreek leaves	2.40
7.	Spinach	0.58
8.	Raisins	0.88

Since the ascorbic acid enhances iron absorption the content of it is esteemed in the below table.

Table.1.6.Provenance of Ascorbic acid in fruits and vegetables

(-Bhuvaneshwari .S.,et al,2015)

S.No.	Source	Ascorbic acid content(mg/100g)
1.	Apple	14.97
2.	Fig	10.53
3.	Ground nut	5.44
4.	Soya bean	3.29
5.	Dates	1.99
6.	Fenugreek leaves	3.81
7.	Spinach	13.46
8.	Raisins	4.71

1.6.Iron Fortifications as a part of Iron sustenance

(-Ricardo Uauy et al.,2002)

Fortification is the worldwide methodology used for the lack of bioavailability of iron in foods to combat iron deficiency but the impact of it is not much documented. There are many practical and technical barriers arising in the production of fortified iron products. The staple foods like wheat, maize and rice are fortified with iron. Ferrous sulfate and fumarate are predominantly utilized. Fortifications have a wide range of limitations due to which therapeutics for iron deficiency is promoted.

1.7.Iron Induction assay

(-Sarkar et al.,2007)

It is estimated that the herbal preparations prescribed in Ayurveda familiarly known as “Punarnava Mandura” for anaemic patients contains iron proportions (known as Mandura in Sanskrit) is composed of certain herbs listed in the table below. Hematinic evaluation of mandura (iron particles) on Mercury Chloride significantly increased the haemoglobin level in the anaemic rats.

Table.1.7.Illustrations of iron induction scrutiny

(-Swarnim Gupta et al.,2013)

S.no.	Ministrations	Serum iron induction(ng/mg cell protein)
1.	Saline control	17
2.	FeCl ₃ and Ascorbic acid	1119
3.	B.diffusa (Punarnava leaves)	14
4.	T.ammi(Ommum seeds)	14
5.	A.paniculatus (Amaranth seeds)	20

6.	L.sativum (Garden cress seeds)	13
7.	M.sativa (Alfa alfa seeds)	15
8.	S.indicum(Tila seeds)	18
9.	A.racemosus(Asparagus roots)	17
10.	P.Longum (Pipli fruits)	15

1.8.Nutritional configuration in the iron-potent plant –*Celosia argentea*

(-Oluwafunmilayo Dorcas Adegbaaju et al,2019).

Table.1.8.Nutriments conformation

S.No	Nutrient	Percentage composition (%)
1.	Carbohydrate	45.50
2.	Protein	5.17
3.	Fibre	3.53
4.	Fat	1.10
5.	Ash	22.43
6.	Dry matter	15
7.	Moister	8.84

The consignment of energy in Kilo-calorie per 100g is 234.45. It is reported that 800g of the plant contains 280g of sugar molecule, 43g of amino acid content, 35.7 g of fibrous mass, 16.65g of lipid content, 178.4g of residue, 163g of dry matter and 80g of water content. (-Gloria aderonke otunola et al., 2019)

1.9.Mineral configuration in iron-potent plant-*Celosia argentea*

(- Oluwafunmilayo Dorcas Adegbaaju et al,2019).

Table.1.9.Conformation of inorganic constituents

S.No.	Element	Constitution (mg/100g)
1.	Calcium	178.08
2.	Iron	15.25
3.	Magnesium	39.64
4.	Manganese	1.73
5.	Potassium	128.33
6.	Sodium	71.32
7.	Zinc	7.25
8.	Copper	3.75
9.	Phosphorous	38.01

The estimation illustrates that 100g of the plant contains 0.176% of manganese, 0.375% of copper, 0.82% of zinc, 2.74% of iron, 5.33% of phosphorous, 5.54% of magnesium, 10.5% of sodium, 27.9% of potassium and 29.1% of calcium. (-Antony Jide afolayan ,et al,2013)

1.10.Vitamin configuration in iron-potent plant-*Celosia argentea*

(- Oluwafunmilayo Dorcas Adegbaaju et al,2019).

Table.1.10.Fibre constituents.

S.no.	Vitamin	Constitution (mg/100g)
1.	Retinol	48.20
2.	Thiamin	0.09
3.	Ascorbic acid	59
4.	Tocopherol	28.3

The data describes the presence of 0.0001% of Vitamin B ,with 0.028% of vitaminE ,0.058% Of vitamin C and 0.046% of vitamin A proportions.

1.11.Essential amino acid configuration in the iron-potent plant-*Celosia argentea*.

(- Oluwafunmilayo Dorcas Adegbaaju et al,2019).

Table.1.11. Micro peptide constituents.

S.No	Amino acid denotion	Constituent (g/100g)
1.	Arginine	4.85
2.	Valine	4.37
3.	Histidine	2.25
4.	Leucin	6.31
5.	Isoleucin	3.30
6.	Lysine	4.68
7.	Methionine	1.52
8.	Phenylalanine	3.94
9.	Threonine	3.47

The availability of peptide denotes that the plant contributes towards genetic manifestations in the body

1.12. Taxonomic Framework of *Celosia argentea*

-(Oluwafunmilayo Dorcas Adegba et al,2019).

Table.1.12. Codific Classification.

Kingdom	Plantae
Clade	Tracheophytes
Clade	Angiosperms
Clade	Eudicots
Order	Caryophyllales
Family	Amaranthaceae
Genus	Celosia
Species	argentea
Binomial name	Celosia argentea

Celosia argentea is a vast range of flora with vascular system to conduct water and nourishments with two cotyledon which is edible. It is a flowering variety used in ornamentation of Amaranthacea family.

1.13. Human transferrin Protein

The human transferrin protein (HTf) is a protein which is present in the blood-plasma of humans. HTf is mainly secreted by the liver and is translated by the TF gene at a size of 76KDa. It is also synthesized by other tissues and organs such as the brain (choroid plexus and ventricular system). It is also present in some of the vertebrates other than humans and in some invertebrates. In humans, transferrin consists of a polypeptide chain of 679 amino acids and two carbohydrate chains. The structure of HTf includes alpha helices and beta sheets forming two domains. It is a glycoprotein and its main function is the iron-binding mechanism that controls the level of free Fe in the biological fluids i.e. iron homeostasis in maintaining iron concentration. Transferrin has two highly specific (FeIII) affinity binding sites in between the two globular lobes of N and C terminal sequences. The optimum pH for the binding is 7.4. The molecular weight of the human transferrin protein is 80KDa. HTf also plays an important role in the production of red blood cells called erythropoiesis and in the areas of active cell division. Transferrin has an iron-bound receptor which is a homodimer linked to a disulphide bond. There are two types of transferrin receptors-TfR1 and TfR2. The TfR1 is bound to human transferrin and the TfR2 is bound to bovine transferrin. The transferrin level is inversely proportional to the inflammation in the surface of the tissue. The quantity of the human transferrin is referred to be ranged from 204 to 360 mg/dL. As an abnormal condition the transferrin level increases for patients with iron deficiencies, during pregnancies and for the individuals consuming oral contraceptives. The decrease in transferrin level leads to a genetic disorder known as atransferrinemia causing complications in heart, liver and in organs. HTf is an anti-cancer protein. HTf has an application in nanotechnology as it can be moved across the blood-brain barrier through the receptor-mediated brain capillaries endothelial cells for the treatment of the diseases like Alzheimer's and Parkinson's by making the nanoparticles the drug carriers bound to transferrin glycoprotein. These transferrin conjugated nanoparticles serve as a non-invasive drug for the therapeutic activity in the central nervous system related diseases.




Figure.1. Structure of Transferrin protein.

2. Aim and objective

AIM :

To anticipate the treatment for iron-deficiency –Anaemia

OBJECTIVE:

- It is terminated by the Virtual screening process
- The physical properties are determined by the database of molinspiration, Swiss ADME
- The online software Patch Dock is accessed with 4.0 RMSD value.

3. Review of Literature:

(-Dorcus Adegaju et al., 2019)

The common name of the plant *Celosia argentea* is Silver cock's comb. It is known as pannakerai in the South Indian language Tamil. It has a wide range of applications and is used as an ancestral food. It is also used as a traditional medicine in the field of Ayurveda, Siddha, Unani and Homeopathy. It is considered as a troublesome weed in some countries which reduces its significance.



Figure.2. Celosia argentea



Figure.3. *Celosia argentea* in Tamil Nadu

3.1. Botanical Description

It is an annual herb and is erect about 0.4 to 2 meters. Inflorescence is dense and silvery.

3.2. Distribution

It is originally from tropical Africa, but it has been spread early throughout Asia and Malaysia (-Smith et al., 1981). In India it is cultivated in Assam, Bihar, Gujarat, Karnataka, Maharashtra and Odisha. (-Pawan Kumar et al., 2011).

3.3. Applications of *Celosia argentea*

(-Sunil Kumar et al., 2011)

Celosia argentea is used as a colouring agent, preservative, flavor enhancer, maintains texture and body of the cuisine, serves as a sweetener and adds to the appearance of the food to which it is added. It replaces saffron (kunkuma poo in Tamil) which is the colouring and flavouring module. It reduces the psychrophilic count and TBARS content in the food it is added. It is rated 7.10/8 in its overall acceptability.

3.4. Biological activities

3.4.1. Antidiabetic activity

Diabetes mellitus is a disease of metabolic disorder caused by the impairment of glucose usage associated with underlying factors for both hypoglycemia and hyperglycemia. Adequate consumption of green leafy vegetables reduces the risk of diabetes (-Harding et al., 101). Anti-diabetic activity of *C. argentea* root extracts on streptozotocin-induced diabetic rats (Ghul et al., 102). The effect of extracts from *C. argentea* at 500 mg/kg dose on diabetic rats after 2 weeks of treatment showed a significant decrease in glycaemic levels from 397.83 ± 9.67 mg/dL to 99.33 ± 1.84 mg/dL, this translates to a reduction of 75%. The alcoholic extracts of *Celosia argentea* seeds have also been reported to reduce blood glucose in alloxan-induced diabetic rats after two weeks. A decrease of 27.8% and 38.8% in the blood glucose level was reported after 6 hours, at 250 and 500 mg/kg dose respectively. Both the aqueous and ethanolic fractions of *C. argentea* exhibited significant hypoglycemic activities on alloxan-induced diabetic rats after oral administration at 800 mg/kg dose. (-Shan et al., 104)

3.4.2. Anti-obesity potential

The low, crude fat content of the genus could be suitable in facilitating initial weight loss and subsequent weight stability. The impact of *C. cristata* extract on human adipogenesis CD34+/CD31- cells, using immunoselection/depletion approaches was evaluated (-Fituussi et al., 105). Results revealed that *C. cristata* extract reduces lipid content of progenitor cells undergoing adipogenic differentiation within 10 days at a dose of 0.5%; and a significant decrease in the expression of C/EBP α gene to a level of 56.0% was recorded. Hence the species could be explored for the treatment and management

3.4.3. Hepatoprotective activity

Liver health maintenance is one of the major therapeutic uses of *Celosia* species in traditional medicine. This has been supported by various modern scientific pharmacological findings. A three-day intragastric administration of celosin A and B (bioactive compounds from the species) at different doses of 1.0, 2.0 and 4.0 mg/kg had a modulatory effect on hepatic enzymes in 0.10% CCl₄-induced liver damage in Kunming mice by lowering the levels of AST, ALT and ALP from 299 ± 77 , 167 ± 26 , 380 ± 72 to 293 ± 54 , 162 ± 42 , 360 ± 75 , respectively, at the highest dose of 4.0 mg/kg (-Xue et al., 106). Celosins from *C. cristata* decreased the level of lipid peroxidation in a carbon tetrachloride (CCl₄)-induced hepatotoxic mice.

The levels of antioxidant enzymes (SOD, CAT and GSH-Px) were reported to increase significantly with an oral dose of 0.1, 0.2 and 0.4 mg/kg. *Celosia cristata* flower extracts protect against tert-butyl hydroperoxide-induced oxidative hepatotoxicity. In vitro, the extracts prevented reactive oxygen species (ROS) generation and

mitochondrial membrane depolarization in t-BHP-induced hepatotoxicity in Chang cells. Also, in vivo administration of *Celosia cristata* flower extracts (100 and 500 mg/kg body weight) orally to rats consecutively for five days before a single dose of t-BHP (2 mmol/kg, i.p.) significantly ($p < 0.05$) protected the liver cells by lowering serum levels of glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) i.e. as well as decreased hepatic lipid peroxidation and serum triglyceride against t-BHP-induced oxidative stress.

3.4.4. Anti-Cancer activity

Celosia species are potent anti-tumor agents. It is reported that 28 µg/mL of methanolic extracts of *C. argentea* showed significant cytotoxic activity comparable to methotrexate, a standard anti-cancer drug (Rub et al., 101); while it is also reported the anti-metastatic effect of *C. cristata* extracts on liver metastasis of murine colon 26-L5 carcinoma cells and that *C. cristata* exerted mitogenic activity on the spleen cells at concentration of 1000 µg/mL (Hayakawa et al., 112). The anti-tumour activities of four triterpenoid saponins from *Celosia* on five human cancer cell lines at concentrations less than 100 µg/mL (Wu et al., 110). Inhibition of cancer cells at concentration range of 24–30 µg/mL was recorded for the entire cancer cells tested. The aerial parts of *Celosia argentea* extracted with 70% ethanol and water, reduced myelosuppression and enhanced immune response against-induced myelosuppression in Swiss mice (Nirmal et al., 113). The effect of ethanolic extract of *C. argentea* on the viability of two cancer cell lines (SiHa and MCF-7) using MTT assay (Rab et al., 110). The outcome of the study showed that *C. argentea* exhibited a potent anti-cancer activity against both cell lines at concentration of 28 µg/mL, but does not have any toxicity effect towards normal cells investigated. The plants from *Celosia* were consumed by prisoners of war in Thailand to prevent nutritionally related diseases and also as an anti-cancer agent (Navarra 114, et al., 114).

3.4.5. Antimicrobial and Anthelmintic potential

The extracts from *Celosia* species has been reported to show inhibitory activities against *Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Candida albicans* and *Aspergillus niger* at concentrations ranging from as low as 3.125 to 50 µg/mL. The antimicrobial activities of *C. cristata* and reported that methanolic and ethanolic extracts of the species inhibited the growth of *S. aureus*, *B. subtilis* and *C. albicans* at 0.125, 0.5 and 1 mg/mL respectively (Yun et al., 116). The aqueous extract of *C. cristata* showed significant anthelmintic activity on adult worms of *Pheretima posthuma* at 100–200 mg/mL (Rubini et al., 112).

3.4.6. Antinociceptive and Antiuro lithiatic activities

A strong antinociceptive effect of the methanolic extract of *C. cristata* in mice at a dose of 400 mg/kg, providing a rationale for its traditional use for the treatment of painful conditions (Islam et al., 118). The antiuro lithiatic activity of ethanolic extract of *C. argentea* seeds in rats (Joshi et al., 119).

The authors found that *C. argentea* seed extracts prevented the formation of kidney stones at doses of 250 and 500 mg/kg, thus preventing impairment of renal function. The extracts of *C. argentea* roots exhibited significant prophylactic effect on renal stone of ethylene glycol induced rats at both the standard drug used in the study (Kachichi et al., 117).

4. Materials and methods

4.1. Ligand preparation

Chemical structures of the 20 ligands namely 1) Celosin G (CID53236073) 2) Celosin E (CID53239472) 3) Celosin F (CID101788473) 4) Celogenamide A (CID11263281) 5) Arachidic Acid (CID10467) 6) Arachidonic Acid (CID 444899) 7) Linoleic Acid (CID5280450) 8) Palmitoleic Acid (CID445638) 9) Hexadecanoic Acid (CID985) 10) Octadecanoic Acid (CID5281) 11) Luteolin 7-O-Glucoside (CID45933934) 12) Celogentin H (CID101236343) 13) Celogentin B (CID20704435) 14) Celogentin C (CID10985937) 15) Celogentin D (CID76185975) 16) Celogentin E (CID 101236340) 17) Celogentin F (CID101236341) 18) Celogentin G (CID101236342) 19) Celogentin J (CID101236344) 20) Celogentin K (CID101344858) were retrieved from Pubmed compound database (www.pubmed.com)

4.2. Target Protein Identification and Preparation

The three-dimensional structures of the HTf (PDB ID: 1A8F with resolution of 1.8 Å) was obtained from the Research Collaborator for Structural Bioinformatics (RCSB) Protein Data Bank (www.rcsb.org). The protein was pre-processed separately by deleting other chains (A, B, and C) and the ligands (Fe, CO₃), as well as the crystallographically observed water molecules (water without hydrogen bonds).

4.3.Molecular Descriptors Calculation

Molinspiration online database was used to calculate 13 descriptors (www.molinspiration.com); logP, polar surface area, molecular weight, number of atoms, number of O or N, number of OH or NH, number of rotatable bonds, volume, drug likeness including G protein coupled receptors (GPCR) ligand, ion channel modulator, kinase inhibitor, and nuclear receptor ligand, and number of violations to Lipinski's rule, for all selected 20 ligands.

4.4.Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET)

The ADMET test was performed using Discovery Studio® 3.1 (Accelrys, San Diego, USA). ADMET analysis was performed using human intestinal absorption (HIA), aqueous solubility (AS), blood brain barrier (BBB), cytochrome P450 2D6 (CYP2D6), plasma protein binding (PPB), and hepatotoxicity (HT) descriptors.

4.5.Docking studies

Docking studies were carried out by the crystal structure of Human serum transferrin retrieved from protein data bank using patch dock.

5. Results and discussion

The 2D structure of the 20 ligands retrieved are listed in the below table.

Table.5.1.Pubmed data

s.no	Compound name	Compound CID	Canonical SMILES
1.	Celosin G	532360 73	<chem>CC1C(C(C(C(O1)OC(=O)C23CCC(CC2C4=CCC5C6(CCC(C(C6CCC5(C4(CC3)C)C)(C)C(=O)O)OC7C(C(C(C(O7)CO)O)O)C)(C)C)OC8C(C(C(C(O8)C)OC9C(C(C(C(O9)C(=O)O)O)O)O)O)O</chem>
2	Celosin E	53239472	<chem>CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C(=O)O)OC6C(C(C(C(O6)C(=O)O)O)O)O)C)C(=O)O)C2C1)C)C</chem>
3	Celosin F	101788473	<chem>CC1C2C3=CCC4C5(CC(C(C5CCC4(C3(CCC2(CCC1=C)C(=O)O)C)C(=O)O)(C)C(=O)O)OC6C(C(C(O6)O)O)O)C</chem>
4	Celogenamide A	11263281	<chem>CC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CC2=CN(C(C(=O)N1)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C4CCCN4C(=O)C5CCC(=O)N5)C6=CC=CC=C26)C(=O)NC(CCCN)C(=O)O)CO)CC7=CC=CC=C7</chem>
5	Arachidic Acid	10467	<chem>CCCCCCCCCCCCCCCCCCCC(=O)O</chem>
6	Arachidonic Acid	444899	<chem>CCCCC=CCC=CCC=CCC=CCCCC(=O)O</chem>
7	Linoleic Acid	5280450	<chem>CCCCC=CCC=CCCCCCCCC(=O)O</chem>
8	Palmitoleic Acid	445638	<chem>CCCCCCC=CCCCCCCCC(=O)O</chem>
9	Hexadecanoic Acid	985	<chem>CCCCCCCCCCCCCCCCC(=O)O</chem>
10	Octadecanoic Acid	5281	<chem>CCCCCCCCCCCCCCCCC(=O)O</chem>
11.	Luteolin 7-O-Glucoside	45933934	<chem>C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)OC4C(C(C(C(O4)CO)O)O)O)O)O</chem>
12.	Celogentin H	101236343	<chem>CCC(C)C1C(=O)NC2CC3=C(NC4=C3C=CC(=C4)C(C(C(=O)NC(C(=O)N1)CC(C)C)NC(=O)C(=O)C5CCC(=O)N5)C(C)C)N6C=C(CC(NC(=O)CNC(=O)C(C2=O)CCCN=C(N)N)C(=O)NC(CC(=O)O)C(=O)O)N=C6</chem>
13.	Celogentin B	20704435	<chem>CC(C)CC1C(=O)NC(C(=O)NC2CC3=C(NC4=C3C=CC(=C4)C(C(C(=O)N1)NC(=O)C5CCC(=O)N5)C(C)C)N6C=C(CC(NC(=O)C(NC2=O)CCCN=C(N)N)C(=O)NC(CC7=CN=CN7)C(=O)O)N=C6)C(C)C</chem>

14.	Celogentin C	10985937	<chem>CC(C)CC1C(=O)NC(C(=O)NC2CC3=C(NC4=C3C=CC(=C4)C(C(C(=O)N1)NC(=O)C5CCC(=O)N5)C(C)C)N6C=C(CC(NC(=O)C(NC(=O)C7CCCN7C2=O)CCCN=C(N)N)C(=O)O)N=C6)C(C)C</chem>
15.	Celogentin D	76185975	<chem>CC(C)CC1C(=O)NC(C(=O)NC2CC3=C(NC4=C3C=CC(=C4)C(C(C(=O)N1)NC(=O)C5CCC(=O)N5)C(C)C)N6C=C(CC(NC(=O)C(NC2=O)CCCN=C(N)N)C(=O)NC(CC7=CN=CN7)C(=O)NC(CCCCN)C(=O)O)N=C6)C(C)C</chem>
16.	Celogentin E	101236340	<chem>CC(C)CC1C(=O)NC(C(=O)NC2CC3=C(NC4=C3C=CC(=C4)C(C(C(=O)N1)NC(=O)C(=O)C5CCC(=O)N5)C(C)C)N6C=C(CC(NC(=O)CNC(=O)C(C2=O)CCCN=C(N)N)C(=O)NC(CC(=O)O)C(=O)O)N=C6)C(C)C</chem>
17.	Celogentin F	101236341	<chem>CC(C)CC1C(=O)NC(C(=O)NC2CC3=C(NC4=C3C=CC(=C4)C(C(C(=O)N1)NC(=O)C(=O)C5CCC(=O)N5)C(C)C)N6C=C(CC(NC(=O)CNC(=O)C(C2=O)CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)O)N=C6)C(C)C</chem>
18.	Celogentin G	101236342	<chem>CCC(C)C1C(=O)NC2CC3=C(NC4=C3C=CC(=C4)C(C(C(=O)NC(C(=O)N1)CC(C)C)NC(=O)C(=O)C5CCC(=O)N5)C(C)C)N6C=C(CC(NC(=O)CNC(=O)C(C2=O)CCCN=C(N)N)C(=O)O)N=C6</chem>
19.	Celogentin J	101236344	<chem>CCC(C)C1C(=O)NC2CC3=C(NC4=C3C=CC(=C4)C(C(C(=O)NC(C(=O)N1)CC(C)C)NC(=O)C(=O)C5CCC(=O)N5)C(C)C)N6C=C(CC(NC(=O)CNC(=O)C(C2=O)CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)O)N=C6</chem>
20.	Celogentin K	101344858	<chem>CC(C)CC1NOC(C(C2=CC3=C(C=C2)C(CC(NOC(NO1)C(C)C)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NC(CC4=CN=CN4)C(=O)O)(C(=O)N3)O)C(C)C)NC(=O)C5CC(=O)N5</chem>

5.1. Molecular Descriptors Analysis

Drug development is expensive and the most poorly behaved compounds toward physicochemical properties need to be weeded out early to prevent or minimize failure in pre-clinical stages/Phase I clinical trials. Thus, screening compounds based on Lipinski's rule of five is important which in the candidate drugs that comply with rule have been shown to have lower attrition during clinical trials. In the present study, all the 20 ligands selected from *Celosia argentea* composition showed no violation toward Lipinski's rule. The bioactivity score, was set to be (>0) active, (−5.0 to 0.0) moderate active, (<−5.0) inactive. However, for most descriptors these compounds exhibited active to moderate active scores with none showing inactive score (<−5.0) as shown in the below table.

Table.5.2.Physical properties of ligands

S.No.	Ligands	milogP	TPSA	nato ms	M W	nON	nOHN H	Nviolati ons	nrotb	volume
1.	CelosinG	0.28	388.0 5	78	11 17. 24	24	13	3	12	995.73
2.	CelosinE	2.68	211.2 8	48	67 8.8 2	12	7	3	5	623.93
3.	CelosinF	1.83	211.2 8	47	66 2.7 7	12	7	3	5	602.03
4.	CelogenamideA	−3.67	361.8 1	79	10 92. 22	24	13	3	18	980.70

5.	Archidic acid	8.73	37.30	22	31 2.5 4	2	1	1	18	358.63
6.	Archidonic acid	6.42	37.30	22	30 4.4 7	2	1	1	14	333.88
7.	Linoleic acid	6.86	37.30	20	28 0.4 5	2	1	1	14	312.65
8.	Palmitoleic acid	6.57	37.30	18	25 4.4 1	2	1	1	13	285.24
9.	Hexadecanoic acid	7.06	37.30	18	25 6.4 3	2	1	1	14	291.42
10.	Octadecanoic acid	8.07	37.30	20	28 4.4 8	2	1	1	16	325.03
11.	Luteolin7Oglucoside	0.19	190.28	32	44 8.3 8	11	7	2	4	364.19
12.	Celogentin H	-3.94	439.55	81	11 29. 24	28	15	3	17	1008.13
13.	Celogentin B	-3.15	396.79	77	10 67. 22	26	15	3	15	961.79
14.	CelogentinC	-2.54	359.32	74	10 27. 20	24	13	3	11	932.70
15.	CelogentinD	-4.19	451.91	86	11 95. 40	29	18	3	21	1088.50
16.	CelogentinE	-4.37	439.55	80	11 15. 22	28	15	3	16	991.33
17.	CelogentinF	-4.52	466.66	83	11 56. 32	29	18	3	18	1043.77
18.	CelogentinG	-2.55	373.15	73	10 14. 15	24	13	3	13	916.11
19.	CelogentinJ	-4.17	466.66	84	11 70. 34	29	18	3	19	1060.57
20.	CelogentinK	-2.59	388.99	70	98 5.1 1	26	16	3	19	889.28

5.2. ADMET Analysis

The ADMET (Absorption,Distribution,Metabolism,Excretion and Toxicity) profile of 20 ligands is listed in the table below.

Table.5.3.ADMET figures

S.n o.	Ligand	GI absorpti on	BBB permea nt	P-gp substra te	CYP1A 2 inhibit or	CYP2C 19 inhibit or	CYP2C 9 inhibit or	CYP2D 6 inhibit or	CYP3A 4 inhibit or	LogKp(ski n permeati on)
1.	Celosin G	Low	No	Yes	No	No	No	No	No	- 12.51cm/ s
2.	Celosin E	Low	No	Yes	No	No	No	No	No	- 7.57cm/s
3.	Celosin F	Low	No	No	No	No	No	No	No	- 9.46cm/s
4.	Celogenami deA	Low	No	Yes	No	No	No	No	No	- 13.27cm/ s
5.	Arachidic acid	Low	No	No	Yes	No	No	No	No	- 1.61cm/s
6.	Arachidonic acid	High	No	No	Yes	No	Yes	No	No	- 3.20cm/s
7.	Linoleic acid	High	Yes	No	Yes	No	Yes	No	No	- 3.05cm/s
8.	Palmitoleic acid	High	Yes	No	Yes	No	Yes	No	No	- 3.18cm/s
9.	Hexadecano ic acid	High	Yes	No	Yes	No	Yes	No	No	- 2.77cm/s
10.	Octadecano ic acid	High	No	No	Yes	No	No	No	No	- 2.19cm/s
11.	Luteolin7-O- glucoside	Low	No	Yes	No	No	No	No	No	- 8.00cm/s
12.	CelogentinH	Low	No	Yes	No	No	No	No	No	- 13.07cm/ s
13.	CelogentinB	Low	No	Yes	No	No	No	No	No	- 12.60cm/ s
14.	CelogentinC	Low	No	Yes	No	No	No	No	No	- 11.98cm/ s
15.	CelogentinD	Low	No	Yes	No	No	No	No	No	- 15.13cm/ s
16.	CelogentinE	Low	No	Yes	No	No	No	No	No	- 13.24cm/ s
17.	CelogentinF	Low	No	Yes	No	No	No	No	No	- 13.96cm/ s
O	CelogentinG	Low	No	Yes	No	No	No	No	No	- 11.58cm/ s
19.	CelogentinJ	Low	No	Yes	No	No	No	No	No	- 13.56cm/ s
20.	CelogentinK	Low	No	Yes	No	No	No	No	No	- 14.13cm/ s

Table.5.4.Bioactivity profile

S.no	Ligand	GPCR ligand	Ion channel	Kinase inhibitor	Nuclear receptor ligand	Protease inhibitor	Enzyme inhibitor
1.	CelosinG	-3.75	-3.85	-3.88	-3.80	-3.69	-3.71
2.	CelosinE	-0.24	-1.08	-1.00	-0.33	0.00	-0.18
3.	CelosinF	-0.14	-0.89	-0.87	-0.19	0.10	0.05
4.	CelogenamideA	-3.71	-3.83	-3.84	-3.86	-3.61	-3.77
5.	Arachidic acid	0.16	0.05	-0.13	0.23	0.14	0.18
6.	Arachidonic acid	0.32	0.16	-0.09	0.35	0.19	0.35
7.	Linoleic acid	0.29	0.17	-0.16	0.31	0.12	0.38
8.	Palmitoleic acid	0.08	0.08	-0.35	0.14	-0.04	0.26
9.	Hexadecanoic acid	0.02	0.06	-0.33	0.08	-0.04	0.18
10.	Octadecanoic acid	0.11	0.05	-0.20	0.17	0.06	0.20
11.	Luteolin7-0-glucoside	0.09	-0.02	0.15	0.27	-0.01	0.42
12.	CelogentinH	-3.71	-3.82	-3.88	-3.91	-3.56	-3.76
13.	CelogentinB	-3.63	-3.75	-3.80	-3.88	-3.52	-3.72
14.	CelogentinC	-3.54	-3.71	-3.76	-3.82	-3.21	-3.67
15.	CelogentinD	-3.77	-3.85	-3.89	-3.95	-3.71	-3.83
16.	CelogentinE	-3.69	-3.81	-3.86	-3.90	-3.54	-3.75
17.	CelogentinF	-3.75	-3.85	-3.89	-3.92	-3.62	-3.79
18.	CelogentinG	-3.54	-3.72	-3.78	-3.78	-3.04	-3.63
19.	CelogentinJ	-3.76	-3.85	-3.90	-3.90	-3.64	-3.80
20.	CelogentinK	-3.47	-3.74	-3.76	-3.81	-3.81	-3.64

5.3.Docking studies with HTf

The Docking survey includes the compound CelogentinD had the maximum interactions whereas the compounds CelogentinE,Palmitoleic acid,octadecanoic acid,hexadecanoic acid etc had no interaction,the rest had medium level of iron-binding at the amino acid site lysine,Threonine,Serine,Tyrosine etc.

Table.5.5.Binding affinities

S.No	Compound name	ACE value	No. of interactions	Amino acid binding site	Wavelength(resolution)
1.	Celosin G	-322.1	one	Thr93	2.1
2.	Celosin E	-24.30	three	Tyr45 Arg50 Asn75	3.4 3.2 2.7
3.	Celosin F	-306.9	one	Tyr317	2.3
4.	CelogenamideA	-147.7	four	Tyr238 Tyr238 His300 Lys276	2.9 2.4 3.1 3.0
5.	Arachidic acid	-86.85	Nil	Nil	Nil
6.	Arachidonic acid	-227.6	three	Leu293 Arg124 Arg124	2.4 2.7 3.1
7.	Linoleic acid	-82.96	Nil	Nil	Nil

8.	Palmitoleic acid	-199.0	Nil	Nil	Nil
9.	Hexadecanoic acid	-199.4	Nil	Nil	Nil
10.	Octadecanoic acid	-92.22	Nil	Nil	Nil
11.	Luteolin7Oglucosi-de	-148.8	four	Thr181 Lys196 Ser189 Ser189	2.8 2.9 2.9 2.2
12.	Celogentin H	-154.0	three	Lys291 Lys291 Lys291	2.9 2.1 2.5
13.	Celogentin B	-196.2	three	Asn75 Arg50 Ala162	2.8 3.3 2.2
14.	Celogentin C	-415.4	two	Tyr136 Tyr136	3.1 2.6
15.	Celogentin D	-193.9	five	Trp128 Arg327 Arg327 Tyr45 Trp128	3.2 2.5 3.3 2.6 2.6
16.	Celogentine E	-324.3	Nil	Nil	Nil
17.	Celogentin F	-105.6	three	Tyr45 Tyr45 Tyr68	2.9 2.3 3.3
18.	Celogentin G	-194.31	three	Arg50 Ser44 Gly176	3.3 3.2 2.9
19.	Celogentin J	-267.7	two	Arg50 Asp163	2.9 3.2
20.	Celogentin K	-295.5	Nil	Nil	Nil




Figure.4. Celogentin D linkage with HTf




Figure.5.Luteolin7-O-glucoside linkage with HTf

Figure.6.CelogenamideA linkage with HTf






Figure.7.CelosinE linkage with HTf



5.4.FTIR Repercussion

The FTIR analysis indicated the presence of trace metals in *Celosia argentea* which includes iron ,copper,zinc etc

Figure.8.FTIR output



6. Conclusions

In the present study, 13 ligands out of 20 in *Celosia argentea* showed the potential to dock and bind with HTf(1A8F). Among the ligands only hexadecanoic acid, octadecanoic acid, CelogentinE, Palmitoic acid, Linoleic acid, CelogentinK and Arachidic acid failed to Dock with HTf. Hence it is strongly suggested that the results of this present study might provide a new insight in understanding these 20 ligands as potential acceptors in relation to the treatment of iron-deficiency disease.

7. Future Directions:

This insilico project can be further followed by invivo studies through the administration of the effective components to the laboratory animals and estimating the efficiency of the plant in curing anaemia.

8. Reference:

1. KUMARI, TD SANDHYA, and MA SINGARA CHARYA. "DOCKING STUDIES ON BIOACTIVE COMPOUNDS OF NYCTANTHES ARBOR-TRISTIS."
2. Narayanaswamy, Radhakrishnan, Lam Kok Wai, and Intan Safinar Ismail. "In silico analysis of selected honey constituents as human neutrophil elastase (HNE) and matrix metalloproteinases (MMP 2 and 9) inhibitors." *International Journal of Food Properties* 18, no. 10 (2015): 2155-2164.
3. Mao, Wenfu, Mary A. Schuler, and May R. Berenbaum. "Disruption of quercetin metabolism by fungicide affects energy production in honey bees (*Apis mellifera*)." *Proceedings of the National Academy of Sciences* 114, no. 10 (2017): 2538-2543.
4. Krishnan, N. Radha, R. D. Jeffery, M. Martyniuk, R. C. Woodward, M. Saunders, J. M. Dell, and L. Faraone. "Preparation and characterization of cerium substituted bismuth dysprosium iron garnets for magneto-optic applications." *IEEE Transactions on Magnetics* 52, no. 7 (2016): 1-4.
5. Ge, Ruijing, Xiaowei Hou, Kirsten Brookshire, N. Radha Krishnan, Dilusha Silva, John Bumgarner, Yinong Liu, Lorenzo Faraone, and Mariusz Martyniuk. "Nanoindentation of Si 1- x Ge x thin films prepared by biased target ion beam deposition." In *2014 Conference on Optoelectronic and Microelectronic Materials & Devices*, pp. 210-213. IEEE, 2014.
6. Adegbaaju, Oluwafunmilayo Dorcas, Gloria Aderonke Otunola, and Anthony Jide Afolayan. "Potential of *Celosia* species in alleviating micronutrient deficiencies and prevention of diet-related chronic diseases: a review." *AIMS Agriculture and Food* 4, no. 2 (2019): 458.

7. Kolade, Olukunle, Derald A. Harp, Curtis Jones, and Jose Lopez. "Effects of zinc fertilization on growth and leaf nutrient content of *Celosia argentea* L." *Journal of Applied Horticulture* 20, no. 3 (2018).
8. Fawusi, M. O. A., D. P. Ormrod, and A. M. Eastham. "Response to water stress of *Celosia argentea* and *Corchorus olitorius* in controlled environments." *Scientia horticulturae* 22, no. 1-2 (1984): 163-171.
9. Liu, Jie, Lingyun Mo, Xuehong Zhang, Shiyin Yao, and Yixuan Wang. "Simultaneous hyperaccumulation of cadmium and manganese in *Celosia argentea* Linn." *International journal of phytoremediation* 20, no. 11 (2018): 1106-1112.
10. Noinaj, Nicholas, Susan K. Buchanan, and Cynthia Nau Cornelissen. "The transferrin-iron import system from pathogenic *N. eisseria* species." *Molecular microbiology* 86, no. 2 (2012): 246-257.
11. Nidavani, Ramesh B., A. M. Mahalakshmi, M. Seema, and K. L. Krishna. "PHARMACOLOGY OF CELOSIA ARGENTEA L." *Journal of atoms and Molecules* 4, no. 1 (2014): 635.
12. Rub, Rukhsana A., Manohar J. Pati, Areej A. Siddiqui, Alpna S. Moghe, and Nasreen N. Shaikh. "Characterization of anticancer principles of *Celosia argentea* (Amaranthaceae)." *Pharmacognosy research* 8, no. 2 (2016): 97.
13. Usunomena, Usunobun, and Ekpemupolo I. Samuel. "Phytochemical analysis, mineral composition and in vitro antioxidant activities of *Celosia argentea* leaves." *Magnesium* 122 (2016): 4-01.
14. FM, OLOYEDE, and OLOYEDE FA. "Effect of Plant Maturity on the Antioxidant Profile of *Amaranthus cruentus* L. and *Celosia Argentea* L." *Bull. Env. Pharmacol. Life Sci. Volume 2* (2013): 18-21.
15. Baker, Edward N., Heather M. Baker, and Richard D. Kidd. "Lactoferrin and transferrin: functional variations on a common structural framework." *Biochemistry and Cell Biology* 80, no. 1 (2002): 27-34.
16. Zhang, Xiu-feng, Lei Chen, Qian-fan Yang, Qian Li, Xiao-ran Sun, Hong-bo Chen, Guang Yang, and Ya-lin Tang. "Spectroscopic and molecular modeling study of cyanine dye interacting with human serum transferrin." *Colloids and Surfaces A: Physicochemical and Engineering Aspects* 469 (2015): 187-193.
17. Ren, Mindong, Genxing Xu, Jianbo Zeng, Carmen De Lemos-Chiarandini, Milton Adesnik, and David D. Sabatini. "Hydrolysis of GTP on rab11 is required for the direct delivery of transferrin from the pericentriolar recycling compartment to the cell surface but not from sorting endosomes." *Proceedings of the National Academy of Sciences* 95, no. 11 (1998): 6187-6192.
18. Barysch, Sina V., Shweta Aggarwal, Reinhard Jahn, and Silvio O. Rizzoli. "Sorting in early endosomes reveals connections to docking-and fusion-associated factors." *Proceedings of the National Academy of Sciences* 106, no. 24 (2009): 9697-9702.
19. Sendamarai, Anoop K., Robert S. Ohgami, Mark D. Fleming, and C. Martin Lawrence. "Structure of the membrane proximal oxidoreductase domain of human Steap3, the dominant ferrireductase of the erythroid transferrin cycle." *Proceedings of the National Academy of Sciences* 105, no. 21 (2008): 7410-7415.
20. Grinter, Rhys, Inokentij Josts, Khedidja Mosbahi, Aleksander W. Roszak, Richard J. Cogdell, Alexandre MJJ Bonvin, Joel J. Milner et al. "Structure of the bacterial plant-ferredoxin receptor FusA." *Nature communications* 7, no. 1 (2016): 1-10.
21. Chen, Rong, Li Li, and Zhiping Weng. "ZDOCK: an initial-stage protein-docking algorithm." *Proteins: Structure, Function, and Bioinformatics* 52, no. 1 (2003): 80-87.
22. Kim, Dae Heon, Young-Jae Eu, Cheol Min Yoo, Yong-Woo Kim, Kyeong Tae Pih, Jing Bo Jin, Soo Jin Kim, Harald Stenmark, and Inhwon Hwang. "Trafficking of phosphatidylinositol 3-phosphate from the trans-Golgi network to the lumen of the central vacuole in plant cells." *The Plant Cell* 13, no. 2 (2001): 287-301.
23. Peumans, Willy J., Qiang Hao, and Els JM van Damme. "Ribosome-inactivating proteins from plants: more than RNA N-glycosidases?." *The FASEB Journal* 15, no. 9 (2001): 1493-1506.
24. Dhungana, Suraj, Céline H. Taboy, Damon S. Anderson, Kevin G. Vaughan, Philip Aisen, Timothy A. Mietzner, and Alvin L. Crumbliss. "The influence of the synergistic anion on iron chelation by ferric

- binding protein, a bacterial transferrin." *Proceedings of the National Academy of Sciences* 100, no. 7 (2003): 3659-3664.
25. Ghule, Santosh, T. Prakash, D. Kotresha, Roopa Karki, V. Surendra, and Divakar Goli. "Anti-diabetic activity of *Celosia argentea* root in streptozotocin-induced diabetic rats." *International Journal of Green Pharmacy (IJGP)* 4, no. 3 (2010).
 26. Camaschella, Clara. "Iron-deficiency anemia." *New England journal of medicine* 372, no. 19 (2015): 1832-1843.
 27. Killip, Shersten, John M. Bennett, and Mara D. Chambers. "Iron deficiency anemia." *American family physician* 75, no. 5 (2007): 671-678.
 28. Addison, G. M., M. R. Beamish, C. N. Hales, M. Hodgkins, A. Jacobs, and P. Llewellyn. "An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload." *Journal of Clinical Pathology* 25, no. 4 (1972): 326-329.
 29. Majkić-Singh, N., M. Koprivica, S. Spasić, M. Stojanov, and I. Berkes. "Evaluation of bathophenanthroline method for serum iron assay." *Clinical Chemistry* 26, no. 9 (1980): 1360-1360.
 30. Brune, M., L. Rossander, and L. Hallberg. "Iron absorption and phenolic compounds: importance of different phenolic structures." *European journal of clinical nutrition* 43, no. 8 (1989): 547-557.
 31. Cook, James D., Sandra A. Dassenko, and Paul Whittaker. "Calcium supplementation: effect on iron absorption." *The American journal of clinical nutrition* 53, no. 1 (1991): 106-111.
 32. Disler, PBe, S. R. Lynch, R. W. Charlton, J. D. Torrance, T. H. Bothwell, R. B. Walker, and Fatima Mayet. "The effect of tea on iron absorption." *Gut* 16, no. 3 (1975): 193-200.
 33. Hurrell, Richard F., Marcel-A. Juillerat, Manju B. Reddy, Sean R. Lynch, Sandra A. Dassenko, and James D. Cook. "Soy protein, phytate, and iron absorption in humans." *The American journal of clinical nutrition* 56, no. 3 (1992): 573-578.
 34. Morck, Timothy A., S. R. Lynch, and J. D. Cook. "Inhibition of food iron absorption by coffee." *The American journal of clinical nutrition* 37, no. 3 (1983): 416-420.
 35. Oski, Frank A., and Stephen A. Landaw. "Inhibition of iron absorption from human milk by baby food." *American Journal of Diseases of Children* 134, no. 5 (1980): 459-460.
 36. Layrisse, Miguel, María Nieves García-Casal, Liseti Solano, María Adela Barón, Franklin Arguello, Daisy Llovera, José Ramírez, Irene Leets, and Eleonora Tropper. "Vitamin A reduces the inhibition of iron absorption by phytates and polyphenols." *Food and Nutrition Bulletin* 19, no. 1 (1998): 3-5.
 37. Schneidman-Duhovny, Dina, Yuval Inbar, Ruth Nussinov, and Haim J. Wolfson. "PatchDock and SymmDock: servers for rigid and symmetric docking." *Nucleic acids research* 33, no. suppl_2 (2005): W363-W367.
 38. Rehman, Najeeb Ur, Raeid MM Abed, Hidayat Hussain, Husain Yar Khan, Ajmal Khan, Abdul L. Khan, Majid Ali et al. "Anti-proliferative potential of cyclotetrapeptides from *Bacillus velezensis* RA5401 and their molecular docking on G-protein-coupled receptors." *Microbial pathogenesis* 123 (2018): 419-425.
 39. Jain, Amita, and Pramodkumar P. Gupta. "In silico Comparative Molecular Docking Study and Analysis of Glycyrrhizin from *Abrus precatorius* (L.) against Antidiabetic Activity." *European Journal of Medicinal Plants* (2015): 212-222.
 40. Kumar, Sunil, Z. F. Bhat, and Pavan Kumar. "Effect of apple pulp and *Celosia argentea* on the quality characteristics of Shrikhand." *Am. J. Food Technol* 6, no. 9 (2011): 1-8.
 41. Narayanaswamy, Radhakrishnan, Lam Kok Wai, and Norhaizan Mohd Esa. "Molecular docking analysis of phytic acid and 4-hydroxyisoleucine as cyclooxygenase-2, microsomal prostaglandin E synthase-2, tyrosinase, human neutrophil elastase, matrix metalloproteinase-2 and-9, xanthine oxidase, squalene synthase, nitric oxide synthase, human aldose reductase, and lipoxygenase inhibitors." *Pharmacognosy magazine* 13, no. Suppl 3 (2017): S512.
 42. Lal, Bharat, and Neeraj Mishra. "Importance of *Embelia ribes*: An update." *International Journal of Pharmaceutical Sciences and Research* 4, no. 10 (2013): 3823.